ARTICLE | Targets & Mechanisms
For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD
Biogen to evaluate Pfizer asset to normalize circadian rhythm-associated Alzheimer’s, Parkinson’s symptoms
January 13, 2020 10:16 PM UTC
Updated on Jan 17, 2020 at 10:10 PM UTC
Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease.
Monday’s deal is Biogen’s second in a week seeking to expand its neurology portfolio as it readies to submit a BLA for its flagship AD therapy aducanumab this year. The company partnered with Camp4 Therapeutics Corp. on Friday to discover CNS targets in microglial cells (see “Camp4’s Platform to Discover CNS Targets” and “Biogen’s Aducanumab Pleases Investors, Confounds Doctors”). ...